Bernstein raises Cigna stock price target on 2027 growth outlook

Bernstein raised Cigna's (CI) price target to $390, citing 2027 growth outlook and undervaluation. CI trades at $303.13, 5% below 52-week high. Q3 2026 earnings beat estimates, with revenue at $73.7B and adjusted EPS at $7.98. CI raised full-year EPS outlook to $30.60.

Original reporting
Published Nov 11, 2026, 10:32 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 10:39 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CI
Bullish
high confidence
Mentioned
$CI
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CIBullishMed
01

Why it matters

The upgrade and earnings beat provide fresh, material information that could drive short-term buying interest in CI.

02

Market read

Cigna's earnings beat and higher guidance, combined with an analyst target raise, create a bullish catalyst for the stock and may influence the broader health insurance sector.

03

What to watch

Potential regulatory scrutiny on pharmacy benefits could temper upside.

Relevance 8/10Novelty 8/10Timing: premarket today

Background

Bernstein SocGen Group adjusted its price target for Cigna after the insurer posted Q3 2026 results that beat expectations and raised its full-year earnings outlook.

Company-level read

Ticker impact

$CIBullishHigh confidence
Context

Bernstein raised its price target on Cigna to $390 and reported Cigna's Q3 2026 earnings beat and raised full-year guidance.

Expected impact

likely upward pressure as the market prices in the higher target and stronger guidance

Evidence & confidence

Target increase and earnings beat are fresh primary disclosures for a large-cap insurer, indicating improved outlook.

Market effects

Positive signal for health insurance sector as earnings beat may lift peers.

U.S. market may see modest gains in financials.

Limited to U.S. insurers, no broad global effect.

Counterpoint

Some investors may view the modest target raise as insufficient given long-term margin pressures in PBM.

Key entities

  • Cigna Group

    U.S. health services insurer (ticker CI).

  • Bernstein SocGen Group

    Research firm that raised the price target.

Related articles

$UNHMed

UnitedHealth and other insurance stocks drag down the Dow after CMS proposes new anti-fraud rule

UnitedHealth (UNH), Humana (HUM), Cigna (CI), and CVS Health (CVS) stocks fell 8%, 8%, 2%, and 3% respectively, dragging down the Dow after CMS proposed a new anti-fraud rule. The rule, called CRUSH, aims to increase audits and recover improper payments, potentially saving $90B over 10 years. Oppenheimer analysts expect legal challenges and note savings may not be broad.

$UNHHighAI 8/10

Positive Medicaid signals, open enrollment trends: Recapping major payers' Q3 results

UnitedHealth Group reported Q3 profit of $4.1B (up from $2.3B YoY) and revenue of $112.7B. CVS Health earned $2.2B (up from a $4B loss YoY) on $108.4B revenue, announcing a split of its pharmacy business. Cigna and Elevance Health each posted $1.4B profit. Centene reduced losses to $71M (from $6.6B YoY) on $50.6B revenue. Humana saw $162M profit (down from $195M) on $41.15B revenue, with positive Medicare enrollment trends.

$CIHighAI 8/10

What Cigna Group (CI) Said on Its Q3 Earnings Call

Cigna Group (CI) reported Q3 2026 adjusted revenue of $73.8B and adjusted earnings of $2.1B, raising its full-year EPS outlook to at least $30.60. Cigna Healthcare saw 9% revenue growth, while Evernorth's revenue rose 6%. The company expects 10% EPS growth in 2027, with cost savings targeting $3B by 2030.